fenfluramine Fintepla Dravet
Selected indexed studies
- Fenfluramine (Fintepla) for Dravet syndrome. (Med Lett Drugs Ther, 2021) [PMID:34550111]
- Dravet syndrome. (Curr Opin Neurol, 2021) [PMID:33395108]
- Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial. (Epilepsia, 2023) [PMID:37543865]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. (2024) pubmed
- Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. (2019) pubmed
- Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice. (2024) pubmed
- Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial. (2020) pubmed
- Fenfluramine (Fintepla) for Dravet syndrome. (2021) pubmed
- Dravet syndrome. (2021) pubmed
- Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial. (2023) pubmed
- International consensus on diagnosis and management of Dravet syndrome. (2022) pubmed
- Recent advances in pharmacotherapy for epilepsy. (2023) pubmed
- Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome. (2025) pubmed